abbrevi
lrti
lower
respiratori
tract
infect
rsv
respiratori
syncyti
viru
urti
upper
respiratori
tract
infect
hematopoiet
stem
cell
transplant
hsct
patient
infect
respiratori
syncyti
viru
rsv
report
complic
clinic
cours
may
progress
mild
upper
airway
congest
lower
respiratori
tract
symptom
increas
morbid
airflow
obstruct
death
proven
treatment
exist
rsv
infect
set
investig
propos
inhal
ribavirin
requir
primari
therapi
despit
limit
data
suggest
use
immunomodul
may
halt
clinic
progress
hypothes
transplant
patient
experi
signific
morbid
mortal
rsv
despit
receiv
ribavirin
therapi
cohort
receiv
test
nasal
secret
common
respiratori
pathogen
includ
rsv
use
viral
realtim
pcr
rtpcr
panel
present
respiratori
symptom
similar
method
rtpcr
cultur
use
identifi
coinfect
patient
consid
upper
respiratori
tract
infect
urti
rsvposit
rtpcr
secret
analysi
plu
rhinorrhea
congest
otiti
media
pharyng
andor
cough
patient
consid
lower
respiratori
tract
infect
lrti
rsvposit
rtpcr
secret
analysi
nasopharyng
swab
wash
endotrach
tube
aspir
bronchoalveolar
lavag
sampl
plu
sign
includ
hypoxia
new
increas
oxygen
requir
andor
infiltr
found
chest
imag
rsv
infect
episod
defin
patient
develop
symptom
fulli
resolv
instanc
singl
patient
experienc
one
rsv
infecti
episod
result
one
admiss
andor
medic
intervent
result
resolut
symptom
four
hundr
fifti
patient
receiv
allogen
hsct
institut
june
decemb
patient
rsv
infecti
episod
median
age
year
time
viru
first
identifi
tabl
statist
signific
differ
distribut
patient
without
rsv
infect
base
age
gender
diagnos
transplant
prepar
regimen
myeloablo
versu
reduc
intens
condit
tbi
versu
nontbi
contain
stem
cell
donor
sourc
specif
gvhd
prophylaxi
medic
use
vivo
tcelldeplet
serotherapi
incid
grade
iiiv
gvhd
neutrophil
platelet
engraft
day
post
hsct
thirti
urti
occur
patient
four
one
episod
three
four
patient
alreadi
hospit
time
rsv
infect
eight
urti
diagnos
patient
concurr
virus
influenza
influenza
b
rhinoviru
adenoviru
coronaviru
one
patient
singl
document
urti
episod
empir
treat
antibiot
communityacquir
pneumonia
despit
evid
consolid
chest
xray
imag
studi
chest
xray
andor
ct
scan
perform
urti
confirm
absenc
lrti
twenti
urti
diagnos
patient
alreadi
receiv
schedul
ivig
supplement
everi
week
prevent
hypogammaglobulinemia
five
infect
treat
increas
frequenc
addit
dose
ivig
urti
patient
receiv
regularli
schedul
ivig
three
receiv
dose
ivig
treatment
rsv
identifi
addit
four
patient
receiv
palivizumab
twentyon
urti
identifi
patient
receiv
steroid
immunosuppress
medic
time
rsv
identif
four
patient
receiv
treatment
activ
acut
gvhd
five
patient
urti
subsequ
four
seven
lrti
diagnos
time
patient
still
receiv
immunosuppress
patient
receiv
treatment
gvhd
time
rsv
identifi
three
children
receiv
steroid
alon
agent
rsv
identifi
two
six
patient
lrti
year
time
rsv
diagnosi
one
signific
histori
prematur
two
six
patient
carri
diagnosi
bronchiol
obliteran
time
lrti
diagnos
six
seven
lrti
associ
identif
one
respiratori
tract
organ
besid
rsv
includ
metapneumoviru
influenza
rhinoviru
coccidiomycos
adenoviru
haemophilu
influenza
penicillium
nocardia
latter
four
organ
seen
one
singl
rsv
infecti
episod
infiltr
radiolog
studi
increas
effort
breath
note
seven
case
five
seven
episod
two
seven
episod
requir
oxygen
supplement
mechan
ventil
respect
five
seven
lrti
diagnos
time
regularli
schedul
ivig
administ
patient
seven
case
treat
either
increas
frequenc
addit
dose
ivig
one
case
patient
receiv
palivizumab
diagnosi
rsv
confirm
neg
five
seven
case
median
day
rang
pcrposit
neg
result
six
seven
case
result
return
clinic
baselin
remain
case
involv
patient
rapid
multiorgan
system
failur
death
autopsi
confirm
dissemin
coccidiomycosi
minor
hsct
recipi
retrospect
studi
cohort
rsv
infect
present
progress
lrti
viral
lrti
shown
less
common
first
day
post
hsct
nonmyeloabl
regimen
use
howev
patient
lrti
occur
first
day
receiv
reduc
intens
condit
regimen
hsct
patient
receiv
cord
bone
marrow
stem
cell
also
report
higher
mortal
risk
rsv
howev
four
patient
receiv
cord
blood
stem
cell
transplant
seri
present
urti
recov
addit
three
six
patient
lrti
cohort
receiv
bone
marrow
stem
cell
transplant
complet
recov
infect
addit
hsctassoci
risk
factor
report
contribut
rsv
lrti
progress
death
includ
infect
earli
post
transplant
day
neutropenia
anc
cell
per
mm
lymphocytopenia
absolut
lymphocyt
count
cell
per
young
age
year
concomit
immunosuppress
bacteri
coinfect
four
patient
present
infect
neutrophil
engraft
one
lrti
addit
one
nine
infect
occur
patient
anc
present
lrti
suggest
good
outcom
despit
infect
earli
post
hsct
andor
concurr
sever
neutropenia
cohort
young
age
promin
risk
factor
howev
coinfect
reach
statist
signific
eight
urti
six
seven
lrti
diagnos
patient
document
coinfect
comorbid
bronchiol
obliteran
also
significantli
impact
present
progress
treatment
consid
standard
care
rsv
infect
posthsct
shah
et
al
report
inhal
ribavirin
use
alon
ivig
andor
palivizumab
may
prevent
progress
urti
lrti
effect
allcaus
mortal
metaanalysi
examin
use
inhal
ribavirin
plu
ivig
without
palivizumab
show
statist
signific
impact
overal
surviv
chemali
et
al
conclud
low
overal
mortal
observ
pediatr
oncolog
patient
rsvassoci
lrti
due
directli
ribavirin
use
howev
author
fail
show
statist
signific
differ
reduc
risk
progress
urti
lrti
gener
report
retrospect
rigor
control
clinic
letter
editor
trial
patient
receiv
routin
supplement
ivig
everi
week
normal
level
age
maintain
possibl
passiv
immun
provid
patient
infus
analysi
ivig
lot
show
uniform
consist
presenc
antibodi
rsv
rsvtarget
therapi
use
consist
addit
dose
ivig
increas
passiv
immun
without
addit
palivizumab
palivizumab
use
certain
patient
base
physician
prefer
current
avail
guidelin
previou
studi
found
littl
surviv
advantag
patient
treat
palivizumab
ivig
restrict
analysi
patient
receiv
ivig
diagnosi
rsvassoci
infect
made
indic
patient
receiv
regularli
schedul
ivig
post
hsct
maintain
level
normal
age
death
attribut
rsv
infect
patient
overal
six
patient
cohort
progress
lrti
much
lower
previou
report
rsvinfect
hsct
patient
progress
lrti
result
mortal
rate
studi
limit
retrospect
small
number
patient
howev
find
differ
establish
literatur
show
present
pattern
clinic
outcom
better
previous
report
note
outcom
occur
without
use
inhal
ribavirin
previous
report
improv
overal
surviv
